Truong Factors Age and High-Grade Toxicity Risk Into IO Selection in Melanoma
Source: Targeted Oncology, March 2025
EVENT REGION Illinois, Minnesota, Nebraska, Wisconsin
PARTICIPANT LIST Sakeer Hussain, MD | David A. Potter, MD, PhD | Yan Ji, MD | Bety Ciobanu, MD | Rabih Fahed, MD | Nirav Patel, MD
HUSSAIN: He’s 78, and he has pul-monary and hepatic metastasis, so I would see whether he would be able to tolerate a dual immune checkpoint inhibitor such as ipilimumab [Yervoy] plus nivolumab [Opdivo], but if I can’t, I would probably go with nivolumab/ relatlimab [Opdualag]. Otherwise, I’ll choose a single agent.